Table 2.
Association between Change in KCCQ at 3 months (Per 5 KCCQ Point Change from 0) and Study Outcomes
| Unadjusted | Adjusted for Baseline KCCQ | Adjusted for Clinical Variables | |||||
|---|---|---|---|---|---|---|---|
| Outcome | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| All-cause mortality or all-cause hospitalization |
|||||||
| KCCQ | Per 5 point decline from 0 | 1.10 (1.06, 1.14) | <.001 | 1.11 (1.06, 1.15) | <.001 | 1.07 (1.03, 1.12)* | <.001 |
| Per 5 point increase from 0 to 8 | 0.91 (0.88, 0.95) | <.001 | 0.91 (0.87, 0.94) | <.001 | 0.93 (0.90, 0.97)* | <.001 | |
| Per 5 point increase above 8 | 1.04 (0.98, 1.09) | 0.18 | 0.97 (.92, 1.03) | 0.28 | 0.98 (0.92, 1.03)* | 0.42 | |
| All-cause mortality | |||||||
| KCCQ | Per 5 point decline from 0 | 1.12 (1.06, 1.18) | <.001 | 1.13 (1.07, 1.19) | <.001 | 1.10 (1.04, 1.17)† | <.001 |
| Per 5 point increase from 0 to 8 | 0.90 (0.85, 0.94) | <.001 | 0.89 (0.84, 0.94) | <.001 | 0.91 (0.86, 0.96) † | <.001 | |
| Per 5 point increase above 8 | 1.07 (0.99, 1.16) | 0.08 | 1.00 (0.92, 1.09) | 0.96 | 1.02 (0.94, 1.10) † | 0.72 | |
|
Cardiovascular mortality or heart failure hospitalization |
|||||||
| KCCQ | Per 5 point decline from 0 | 1.11 (1.06, 1.16) | <.001 | 1.19 (1.07, 1.17) | <.001 | 1.09 (1.04, 1.14)‡ | <.001 |
| Per 5 point increase from 0 to 8 | 0.90 (0.86, 0.95) | <.001 | 0.89 (0.85, 0.94) | <.001 | 0.92 (0.87, 0.97)‡ | <.001 | |
| Per 5 point increase above 8 | 1.05 (0.98, 1.12) | 0.18 | 0.97 (0.90, 1.04) | 0.41 | 0.98 (0.91, 1.05)‡ | 0.49 | |
Model for all-cause mortality or all-cause hospitalization adjusted for baseline KCCQ score, randomized treatment assignment, dosage of beta-blocker, KCCQ symptom stability, ejection fraction (LVEF), country (US vs non-US), sex, ventricular conduction, Weber class, blood urea nitrogen (BUN), and mitral regurgitation.
Model of all-cause mortality adjusted for baseline KCCQ score, randomized treatment assignment, sex, body mass index, loop diuretic dose, creatinine, exercise duration, ventricular conduction, Canadian Cardiovascular Society angina classification, and LVEF.
Model for cardiovascular mortality or heart failure hospitalization adjusted for baseline KCCQ score, randomized treatment assignment, loop diuretic dose, LVEF, mitral regurgitation, ventricular conduction, KCCQ symptom stability, BUN, race, sex, age, Weber class, VE/VCO2.